Payment overview · 2025
General Payments
$33,680.83
55 reported records · 20 companies
Healthcare provider profile · identity verified
Christopher Lee Stout, M.D.
Allopathic & Osteopathic Physicians|Surgery|Vascular Surgery · ROGERS, AR · NPI 1760697783
Verified facts
What the public records show
CMS Open Payments records show Christopher Lee Stout, M.D. received $33,680.83 in general payments during 2025 across 55 reported records.
AngioDynamics, Inc. accounted for 89.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 30 associated products.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AngioDynamics, Inc. | Unresolved — no canonical attribution shown | $30,000.00 | 89.1% | 1 | 2025 |
| Endologix LLC | Unresolved — no canonical attribution shown | $1,627.93 | 4.8% | 7 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $387.39 | 1.1% | 8 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $291.33 | 0.9% | 7 | 2025 |
| ASAHI INTECC USA, INC. | Unresolved — no canonical attribution shown | $258.72 | 0.8% | 6 | 2025 |
| Reflow Medical Inc | Unresolved — no canonical attribution shown | $252.89 | 0.8% | 5 | 2025 |
| W. L. Gore & Associates, Inc. | Unresolved — no canonical attribution shown | $206.81 | 0.6% | 2 | 2025 |
| Globus Medical, Inc. | Unresolved — no canonical attribution shown | $165.93 | 0.5% | 2 | 2025 |
| Neuros Medical, Inc. | Unresolved — no canonical attribution shown | $120.64 | 0.4% | 3 | 2025 |
| Bard Peripheral Vascular, Inc. | Unresolved — no canonical attribution shown | $75.05 | 0.2% | 1 | 2025 |
| ConvaTec Inc. | Unresolved — no canonical attribution shown | $61.84 | 0.2% | 2 | 2025 |
| InspireMD Ltd | Unresolved — no canonical attribution shown | $37.26 | 0.1% | 1 | 2025 |
| CORDIS US CORP. | Unresolved — no canonical attribution shown | $36.57 | 0.1% | 2 | 2025 |
| Organogenesis Inc. | Unresolved — no canonical attribution shown | $31.34 | 0.1% | 1 | 2025 |
| Becton, Dickinson and Company | Unresolved — no canonical attribution shown | $26.35 | 0.1% | 1 | 2025 |
| Terumo Medical Corporation | Unresolved — no canonical attribution shown | $25.77 | 0.1% | 1 | 2025 |
| Smith+Nephew, Inc. | Unresolved — no canonical attribution shown | $23.63 | 0.1% | 1 | 2025 |
| Paratek Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $19.46 | 0.1% | 1 | 2025 |
| MIMEDX Group, Inc. | Unresolved — no canonical attribution shown | $15.98 | 0.1% | 1 | 2025 |
| Kerecis Limited | Unresolved — no canonical attribution shown | $15.94 | 0.1% | 2 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Long term medical supply or device loan | $30,000.00 | 1 |
| Food and Beverage | $3,680.83 | 54 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Auryon Laser System 100-120 Vac Normalized: auryon laser system 100 120 vac |
Device | AngioDynamics, Inc. | $30,000.00 | 1 | 2025 |
Source payment records
|
|||||
| Alto Abdominal Stent Graft System Normalized: alto abdominal stent graft system |
Device | Endologix LLC | $1,318.76 | 3 | 2025 |
Source payment records
|
|||||
| Asahi Peripheral Vascular Wires Normalized: asahi peripheral vascular wires |
Device | ASAHI INTECC USA, INC. | $236.64 | 5 | 2025 |
Source payment records
|
|||||
| ESPRIT Normalized: esprit |
Device | Abbott Laboratories | $197.16 | 3 | 2025 |
Source payment records
|
|||||
| General - Vascular Intervention Normalized: general vascular intervention |
Device | Boston Scientific Corporation | $173.30 | 2 | 2025 |
Source payment records
|
|||||
| ENDOCROSS Device Normalized: endocross device |
Device | Endologix LLC | $173.17 | 2 | 2025 |
Source payment records
|
|||||
| Torus Stent Graft System Normalized: torus stent graft system |
Device | Endologix LLC | $173.17 | 2 | 2025 |
Source payment records
|
|||||
| Senza Normalized: senza |
Device | Globus Medical, Inc. | $165.93 | 2 | 2025 |
Source payment records
|
|||||
| GORE EXCLUDER Iliac Branch Endoprosthesis Normalized: gore excluder iliac branch endoprosthesis |
Device | W. L. Gore & Associates, Inc. | $158.60 | 1 | 2025 |
Source payment records
|
|||||
| AFX2 Bifurcated Endograft System Normalized: afx2 bifurcated endograft system |
Device | Endologix LLC | $136.00 | 2 | 2025 |
Source payment records
|
|||||
| Ranger Normalized: ranger |
Device | Boston Scientific Corporation | $130.86 | 1 | 2025 |
Source payment records
|
|||||
| Altius Normalized: altius |
Device | Neuros Medical, Inc. | $120.64 | 3 | 2025 |
Source payment records
|
|||||
| RotarexS 6 F x 135 cm Normalized: rotarexs 6 f x 135 cm |
Device | Bard Peripheral Vascular, Inc. | $75.05 | 1 | 2025 |
Source payment records
|
|||||
| PERCLOSE PROSTYLE Normalized: perclose prostyle |
Device | Abbott Laboratories | $69.17 | 3 | 2025 |
Source payment records
|
|||||
| INNOVAMATRIX AC Normalized: innovamatrix ac |
Device | ConvaTec Inc. | $61.84 | 2 | 2025 |
Source payment records
|
|||||
| ENROUTE Transcarotid Neuroprotection System Normalized: enroute transcarotid neuroprotection system |
Device | Boston Scientific Corporation | $49.33 | 1 | 2025 |
Source payment records
|
|||||
| GORE VIABAHN VBX Balloon Expandable Endo Normalized: gore viabahn vbx balloon expandable endo |
Device | W. L. Gore & Associates, Inc. | $48.21 | 1 | 2025 |
Source payment records
|
|||||
| CGuard Prime Carotid Stent System Normalized: cguard prime carotid stent system |
Device | InspireMD Ltd | $37.26 | 1 | 2025 |
Source payment records
|
|||||
| OptiCross 35 Normalized: opticross 35 |
Device | Boston Scientific Corporation | $33.90 | 4 | 2025 |
Source payment records
|
|||||
| VIA MATRIX Normalized: via matrix |
Medical Supply | Organogenesis Inc. | $31.34 | 1 | 2025 |
Source payment records
|
|||||
| Venclose Maven Catheter Normalized: venclose maven catheter |
Device | Becton, Dickinson and Company | $26.35 | 1 | 2025 |
Source payment records
|
|||||
| AZUR CX DETACHABLE Normalized: azur cx detachable |
Device | Terumo Medical Corporation | $25.77 | 1 | 2025 |
Source payment records
|
|||||
| PERCLOSE PROGLIDE Normalized: perclose proglide |
Device | Abbott Laboratories | $25.00 | 1 | 2025 |
Source payment records
|
|||||
| OASIS Normalized: oasis |
Device | Smith+Nephew, Inc. | $23.63 | 1 | 2025 |
Source payment records
|
|||||
| Asahi Coronary Wires Normalized: asahi coronary wires |
Device | ASAHI INTECC USA, INC. | $22.08 | 1 | 2025 |
Source payment records
|
|||||
| MYNX CONTROL Normalized: mynx control |
Device | CORDIS US CORP. | $20.81 | 1 | 2025 |
Source payment records
|
|||||
| NUZYRA Normalized: nuzyra |
Drug | Paratek Pharmaceuticals, Inc. | $19.46 | 1 | 2025 |
Source payment records
|
|||||
| Kerecis GraftGuide Normalized: kerecis graftguide |
Device | Kerecis Limited | $15.94 | 2 | 2025 |
Source payment records
|
|||||
| Kerecis SurgiClose Normalized: kerecis surgiclose |
Device | Kerecis Limited | $15.94 | 2 | 2025 |
Source payment records
|
|||||
| RADIAL 360 Normalized: radial 360 |
Device | CORDIS US CORP. | $15.76 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
No publishable same-company prescribing overlap was found in the loaded Part D year. This does not mean the doctor never prescribed a drug reported elsewhere by a paying company.
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Clopidogrel | Clopidogrel Bisulfate | 75 | 40 |
| Oxycodone Hcl | Oxycodone Hcl | 52 | 47 |
| Xarelto | Rivaroxaban | 42 | suppressed |
| Prednisone | Prednisone | 13 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $33,680.83 · 55 records | AngioDynamics, Inc. | AFX2 Bifurcated Endograft System, AZUR CX DETACHABLE, Altius, Alto Abdominal Stent Graft System, Asahi Coronary Wires, Asahi Peripheral Vascular Wires, Auryon Laser System 100-120 Vac, CGuard Prime Carotid Stent System, ENDOCROSS Device, ENROUTE Transcarotid Neuroprotection System, ESPRIT, GORE EXCLUDER Iliac Branch Endoprosthesis, GORE VIABAHN VBX Balloon Expandable Endo, General - Vascular Intervention, INNOVAMATRIX AC, Kerecis GraftGuide, Kerecis SurgiClose, MYNX CONTROL, NUZYRA, OASIS, OptiCross 35, PERCLOSE PROGLIDE, PERCLOSE PROSTYLE, RADIAL 360, Ranger, RotarexS 6 F x 135 cm, Senza, Torus Stent Graft System, VIA MATRIX, Venclose Maven Catheter | — | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error